F. Schleich (Liège, Belgium), M. Idzko (Vienna, Austria), K. Kostikas (Ioannina, Greece), B. García Cosío Piqueras (Palma de Mallorca, Spain)
Blood eosinophils fluctuation in asthmatics on Omalizumab-a mirror of disease outcomes improvement? L. Maia Santos (Coimbra, Portugal), B. Ramos (Coimbra, Portugal), C. Chaves Loureiro (Coimbra, Portugal)
| |
Comorbidites and uncontrolled asthma in a ‘real life’ population study M. Santibanez (Santander, Spain), J. Férnandez-Fonfría (Santander, Spain), J. López-Caro (Santander, Spain), F. Gómez-Molleda (Santander, Spain), B. Del Rivero Sierra (Santander, Spain), A. Viejo (Santander, Spain), J. Ruiz-Pérez (Santander, Spain), E. Rueda (Santander, Spain), M. Rodríguez (Santander, Spain), C. Martínez-Pérez (Santander, Spain), R. Garrastazu (Santander, Spain), S. Ortiz (Santander, Spain), J. Hernandez-Urculo (Santander, Spain), M. Hierro (Santander, Spain), J. García-Rivero (Santander, Spain)
| |
Clinical characteristics of the Wessex AsThma CoHort of difficult asthma (WATCH) H. Mistry (Southampton, United Kingdom), A. Azim (Southampton, United Kingdom), M. Harvey (Southampton, United Kingdom), Y. Thirlwall (Southampton, United Kingdom), C. Barber (Southampton, United Kingdom), H. Haitchi (Southampton, United Kingdom), C. Newell (Southampton, United Kingdom), R. Djukanovic (Southampton, United Kingdom), P. Howarth (Southampton, United Kingdom), R. Kurukulaaratchy (Southampton, United Kingdom)
| |
Does the nature of adult difficult asthma differ by age of onset? Findings from WATCH. H. Mistry (Southampton, United Kingdom), A. Freeman (Southampton, United Kingdom), Y. Thirlwall (Southampton, United Kingdom), M. Harvey (Southampton, United Kingdom), C. Barber (Southampton, United Kingdom), H. Haitchi (Southampton, United Kingdom), C. Newell (Southampton, United Kingdom), Y. Cheng (Southampton, United Kingdom), J. Varkonyi-Sepp (Southampton, United Kingdom), R. Kurukulaaratchy (Southampton, United Kingdom)
| |
Comorbidities in the difficult asthma clinic: results from WATCH A. Azim (Southampton, United Kingdom), H. Mistry (Southampton, United Kingdom), M. Harvey (Southampton, United Kingdom), Y. Thirlwall (Southampton, United Kingdom), P. Dennison (Southampton, United Kingdom), A. Freeman (Southampton, United Kingdom), C. Newell (Southampton, United Kingdom), H. Haitchi (Southampton, United Kingdom), P. Howarth (Southampton, United Kingdom), R. Kurukulaaratchy (southampton, United Kingdom)
| |
Does early-onset difficult asthma in adulthood differ by sex? Findings from WATCH. H. Mistry (Southampton, United Kingdom), A. Azim (Southampton, United Kingdom), Y. Thirlwall (Southampton, United Kingdom), F. Mitchell (Isle of Wight, United Kingdom), C. Barber (Southampton, United Kingdom), H. Haitchi (Southampton, United Kingdom), C. Newell (Southampton, United Kingdom), P. Dennison (Southampton, United Kingdom), Y. Cheng (Southampton, United Kingdom), R. Kurukulaaratchy (Southampton, United Kingdom)
| |
Does atopy matter in difficult asthma? Results from WATCH A. Azim (Southampton, United Kingdom), H. Mistry (Southampton, United Kingdom), M. Harvey (Southampton, United Kingdom), Y. Thirlwall (Southampton, United Kingdom), J. Varkonyi-Sepp (Southampton, United Kingdom), H. Haitchi (Southampton, United Kingdom), C. Newell (Southampton, United Kingdom), P. Howarth (Southampton, United Kingdom), R. Kurukulaaratchy (Southampton, United Kingdom)
| |
Inflammatory biomarkers in the evaluation of two-year outcomes of omalizumab treatment in severe allergic asthma. J. Hermanowicz-Salamon (Warsaw, Poland), P. Nejman-Gryz (Warsaw, Poland), R. Rubinsztajn (Warsaw, Poland)
| |
Does Exhaled Nitric Oxide Correlate with Established Measures of Asthma Severity? N. Eid (Louisville, United States of America), M. Bricken (Louisville, United States of America), S. Bickel (Louisville, United States of America)
| |
Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year. A. Cerci Neto (Londrina, Brazil), O. Ferreira Filho (Londrina, Brazil), F. Chibana (Londrina, Brazil), M. Ribeiro (Londrina, Brazil), R. Kauffmann (Londrina, Brazil), L. Sugehara (Londrina, Brazil), P. Passarelli (Londrina, Brazil), F. Bijetti (Londrina, Brazil)
| |
Effectiveness of pulmonary rehabilitation programs on persistent asthma. D. Visca (Tradate, Italy), E. Zampogna (Tradate, Italy), E. Heffler (Milano, Italy), F. Puggioni (Milano, Italy), P. Pignatti (Pavia, Italy), F. Racca (Milano, Italy), G. Sotgiu (Sassari, Italy), S. Negri (Varese, Italy), G. Canonica (Milano, Italy), A. Spanevello (Varese, Italy)
| |
Role of blood neutrophilia as a biomarker in asthma F. Ricciardolo (Turin, Italy), A. Folino (Turin, Italy), V. Carriero (Turin, Italy), M. Bullone (Turin, Italy)
| |
Total IgE and Der p 1 (D1) specific IgE in induced sputum (IS) in patients with allergic and non-allergic asthma E. Curto Sánchez (Barcelona, Spain), A. Crespo Lessmann (Barcelona, Spain), E. Mateus Medina (Barcelona, Spain), L. Soto Retes (Barcelona, Spain), A. García Moral (Barcelona, Spain), M. Torrejón Lázaro (Barcelona, Spain), A. Belda Soler (Barcelona, Spain), J. Giner Donaire (Barcelona, Spain), D. Ramos Barbón (Barcelona, Spain), V. Plaza Moral (Barcelona, Spain)
| |
Serum eosinophil cationic protein as a potential biomarker for interleukin-5 antibody treatment in patients with severe uncontrolled eosinophilic asthma M. Wilk (Mainz, Germany), B. Roland (Mainz, Germany), K. Stephanie (Mainz, Germany)
| |
Prognostic value of using FeNO to guide step-down treatment decisions in asthma K. Wang (Oxford, United Kingdom), J. Verbakel (Oxford, United Kingdom), A. Fleming-Nouri (Oxford, United Kingdom), J. Brewin (Oxford, United Kingdom), J. Oke (Oxford, United Kingdom), I. Pavord (Oxford, United Kingdom), M. Thomas (Southampton, United Kingdom)
| |
The Relationship between Fractional exhaled nitric oxide (FeNO) and Asthma Control and Asthma Severity in Asthmatic Adults in Vietnam V. Nguyen Nhu (Ho Chi Minh City, Vietnam), N. Tran Van (Ho Chi Minh City, Vietnam), B. Nguyen Thi Thu (Ho Chi Minh City, Vietnam), M. Thomas (Southampton, United Kingdom), C. Lionis (Crete, Greece), N. Chavannes (Leiden, Netherlands)
| |
Fractional exhaled nitric oxide is associated with more severe asthma S. Korn (Mainz, Germany), L. Lanz (Mainz, Germany), S. Voigt (Mainz, Germany), M. Wilk (Mainz, Germany), R. Buhl (Mainz, Germany)
| |
Measurement of exhaled nitric oxide: comparison of 3 different analyzers S. Korn (Mainz, Germany), M. Wilk (Mainz, Germany), S. Voigt (Mainz, Germany), T. Keller (Leipzig, Germany), R. Buhl (Mainz, Germany)
| |
Comparison of fractional exhaled nitric oxide (FeNO) levels measured by different analysers J. Saito (Fukushima, Japan), M. Kikuchi (Fukushima, Japan), A. Fukuhara (Fukushima, Japan), S. Sato (Fukushima, Japan), M. Rikimaru (Fukushima, Japan), Y. Suzuki (Fukushima, Japan), M. Uematsu (Fukushima, Japan), R. Togawa (Fukushima, Japan), Y. Sato (Fukushima, Japan), T. Nikaido (Fukushima, Japan), Y. Tanino (Fukushima, Japan), M. Munakata (Fukushima, Japan), Y. Shibata (Fukushima, Japan)
| |
Effect of obesity and overweight on the intestine microbiota in patients with asthma. S. Marova (Saint-Petersburg, Russian Federation), N. Shaporova (Saint-Petersburg, Russian Federation), O. Dudina (Saint-Petersburg, Russian Federation)
| |